Octavia Wealth Advisors LLC Has $258,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Octavia Wealth Advisors LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 3,182 shares of the biopharmaceutical company’s stock after acquiring an additional 196 shares during the period. Octavia Wealth Advisors LLC’s holdings in Gilead Sciences were worth $258,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in GILD. PCA Investment Advisory Services Inc. acquired a new stake in Gilead Sciences in the second quarter valued at $25,000. OFI Invest Asset Management acquired a new stake in Gilead Sciences in the third quarter valued at $26,000. Tompkins Financial Corp lifted its stake in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at $29,000. Finally, Sanctuary Wealth Management L.L.C. acquired a new stake in Gilead Sciences in the fourth quarter valued at $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and cut their price target for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Barclays cut their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research note on Monday, February 12th. Royal Bank of Canada dropped their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 14th. Oppenheimer dropped their price objective on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, February 12th. Finally, Cantor Fitzgerald dropped their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $85.36.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $67.31 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $67.18 and a 52 week high of $87.86. The firm has a market cap of $83.81 billion, a price-to-earnings ratio of 14.96, a P/E/G ratio of 0.86 and a beta of 0.19. The firm’s 50-day simple moving average is $72.40 and its 200 day simple moving average is $76.73. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the prior year, the business posted $1.67 earnings per share. Gilead Sciences’s revenue was down 3.7% compared to the same quarter last year. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.06 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.58%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.